echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Zejing Pharmaceutical Jacketinib Hydrochloride Tablets Clinical Trial Application Approved by the U.S. FDA

    Zejing Pharmaceutical Jacketinib Hydrochloride Tablets Clinical Trial Application Approved by the U.S. FDA

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    On April 25, Zejing Pharmaceutical issued an announcement stating that recently, its research product Jacketinib Hydrochloride Tablets clinical trial application was approved by the US FDA for the treatment of medium and high-risk myelofibrosis.

    Jacketinib Hydrochloride Tablets is a small molecule JAK kinase inhibitor new drug independently developed by Zejing Pharmaceutical, which belongs to the first class of new drugs, and Zejing Pharmaceutical has the independent intellectual property rights of this product.
    Jacketinib hydrochloride can inhibit the non-receptor tyrosine Janus related kinases JAK1, JAK2 and JAK3.


    Jacketinib hydrochloride can effectively inhibit the activation of JAK signaling pathway and inhibit the phosphorylation of activator of transcription (STAT), thereby inhibiting downstream gene expression regulated by STAT.


    The first domestic application for Jectinib hydrochloride tablets was submitted for acceptance in March 2016.





    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.